LOGIN  |  REGISTER
Assertio

Bausch Health (NYSE: BHC) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$8.40 0.05 0.60
Volume: 5,264,819
5-Day Change: -2.78%
YTD Change: 33.60%
Market Cap: US$3.060B

Latest News From Bausch Health

September 21, 2023
Bausch Health: League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease Collaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex Rodriguez LAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma , today announced its... Read More
September 18, 2023
Bausch Health Announces CFO Transition Plan
LAVAL, QC / ACCESSWIRE / September 18, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("BHC" or the "Company") today announced that Tom Vadaketh, Executive Vice President, Chief Financial Officer, has resigned from his role to pursue another opportunity, and will be leaving the Company effective October 13, 2023. The Company thanks Mr. Vadaketh for his significant contributions and leadership during a period of... Read More
September 12, 2023
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment Pr UCERIS ® (budesonide) aerosol foam is now available across Canada to treat mild to moderate distal ulcerative colitis in adults. UCERIS is the only glucocorticosteroid rectal foam available in Canada indicated for the induction of remission in... Read More
September 6, 2023
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)
LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the "Acquisition") on a Current Report on... Read More
August 3, 2023
Bausch Health Announces Second-Quarter 2023 Results, Other Key Updates From the Quarter, and Raises Full-Year 2023 Revenue Outlook
Favorable Motion Ruling in Xifaxan® Litigation Reinforces Continuing Salix Growth Strategy Balance Sheet Initiatives Further Enhance Liquidity Profile Continued Evaluation of Optimal Implementation of Potential Bausch + Lomb Distribution Revenue of $2.17 billion, Up 10% Reported and 11% Organic 1 GAAP Net Income Attributable to Bausch Health Companies Inc. of $26 Million Adjusted EBITDA Attributable to Bausch Health... Read More
July 27, 2023
Bausch Health: Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
Scholarships Awarded to Six Students Affected by Dermatologic Conditions LAVAL, QC / ACCESSWIRE / July 27, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the recipients of their 2023 Aspire Higher Scholarship program. The program, which has provided a total of $978,000 in scholarships since launching in 2013, will award six students who have been... Read More
July 13, 2023
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.... Read More
July 11, 2023
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / July 11, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program. For the fourth consecutive year, Salix will be awarding $10,000 each to 10 students... Read More
July 7, 2023
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference
Oral Health Care Companies Celebrate the 100 th ADHA Conference by Highlighting New Data for the Treatment of Periodontal Disease LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its oral health care business, OraPharma, today announced its presence at the American Dental Hygienists' Association (ADHA®) Annual Conference held in Chicago, IL from July 7-9, 2023. ADHA is the largest and... Read More
July 7, 2023
Bausch Health Enters Into $600 Million Financing Facility With KKR
LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned... Read More
June 30, 2023
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.... Read More
June 19, 2023
Bausch Health: Salix Pharmaceuticals to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
Three XIFAXAN® (rifaximin) Research Posters to Be Featured LAVAL, QC / ACCESSWIRE / June 19, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its presence at the European Association for the Study of the Liver ( EASL ) Congress 2023. XIFAXAN® (rifaximin) data was selected for inclusion in the Cirrhosis and its complication's session. EASL... Read More
June 6, 2023
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
LAVAL, QC / ACCESSWIRE / June 6, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg. At the same time, the FDA confirmed in its Letter that it... Read More
May 31, 2023
Bausch Health: OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
Cover Your Bases Campaign Kicks Off Oral Health Month with ARESTIN (minocycline HCI) Patient Ambassador Alex Rodriguez LAVAL, QC , May 31, 2023 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez , to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover... Read More
May 18, 2023
Bausch Health: New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
Novel Trial to Study the Reduction of Certain Pathogens Following Scaling and Root Planing Procedure LAVAL, QC / ACCESSWIRE / May 18, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its oral health care business, OraPharma, today announced the publication of a new study, which showed that ARESTIN ® (minocycline HCI) microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults... Read More
May 17, 2023
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals' motion to modify the Court's final judgment that prevents the U.S. Food and Drug Administration (FDA) from... Read More
May 17, 2023
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the results of its 2023 annual meeting of shareholders (the "Annual Meeting"). The 10 directors nominated at the Company's Annual Meeting held on May 16, 2023, were elected by a vote of the Company's shareholders. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker... Read More
May 10, 2023
Bausch Health Observes Mental Health Awareness Month
LAVAL, QC / ACCESSWIRE / May 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs. With more people finding value in speaking with a mental health professional and seeking treatment, this heightened focus on mental health has never been more... Read More
May 8, 2023
Bausch Health: Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be Presented LAVAL, QC / ACCESSWIRE / May 8, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), the gastroenterology (GI) business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and one of the largest specialty pharmaceutical companies in the world... Read More
May 4, 2023
Bausch Health Announces First-Quarter 2023 Results
First-Quarter revenues of $1.94 billion, up 1% reported and 4% organic 1 Solid revenue growth across core products, led by Xifaxan with 7% reported growth Mid- and late-stage product pipeline advancing Bausch Health provides consolidated full-year guidance, and Bausch Health (excl. B+L) confirms 2023 guidance LAVAL, QC / ACCESSWIRE / May 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the... Read More
May 3, 2023
Bausch Health: RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada
New treatment from Bausch Health, Canada indicated to treat seasonal allergy and associated ocular symptoms in adults, adolescents and children 6 years and older LAVAL, QC , May 3, 2023 /CNW/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray). RYALTRIS has been... Read More
May 1, 2023
Bausch Health: Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
PDUFA Action Date is October 20, 2023 LAVAL, QC / ACCESSWIRE / May 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA) action... Read More
April 24, 2023
Bausch Health: Salix Pharmaceuticals Partners with the Colorectal Cancer Alliance on Community Screening Program
Program Seeks to Increase the Number of People Screened to Help Prevent Colorectal Cancer Diagnoses in Philadelphia LAVAL, QC / ACCESSWIRE / April 24, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced a partnership with the Colorectal Cancer Alliance (Alliance), the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase... Read More
April 13, 2023
Bausch Health to Announce First-Quarter 2023 Results on May 4
LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the... Read More
April 4, 2023
Bausch Health New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
Salix Pharmaceuticals Releases Third Annual Patient Perspectives Report LAVAL, QC / ACCESSWIRE / April 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC).... Read More
March 1, 2023
Bausch Health Companies Announces Changes to its Board of Directors
LAVAL, QC / ACCESSWIRE / March 1, 2023 / Bausch Health Companies Inc. (TSX:BHC) (NYSE:BHC) today announced that Richard De Schutter and Dr. Argeris Karabelas are retiring from the Company's Board of Directors, effective as of the upcoming 2023 annual meeting of shareholders of the Company. Following the retirements of Mr. De Schutter and Dr. Karabelas, the size of the Board will be reduced to 10 directors. "Dick and Jerry... Read More
February 23, 2023
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
Fourth-Quarter revenues of $2.2 billion, flat reported, up 4% organic 1 Full-Year revenues of $8.1 billion, down 4% reported, up 2% organic 1 Unrestricted B+L from BHC covenants Reduced debt by $464 million in the fourth quarter Provides 2023 guidance for Bausch Health (excl. B+L) LAVAL, QC / ACCESSWIRE / February 23, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced its fourth-quarter and full-year... Read More
February 13, 2023
Salix Announces 2023 Gastrointestinal Health Scholars Program
Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals. "At... Read More
February 1, 2023
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior... Read More
December 22, 2022
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans
LAVAL, QC , Dec. 22, 2022 /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLO TM (tazarotene lotion, 0.045% w/w), is now available to patients through the provincial public drug plans of Quebec , Ontario ,... Read More
December 2, 2022
Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case
LAVAL, QB / ACCESSWIRE / December 2, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will... Read More
December 1, 2022
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
Launching in December for Constipation Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Disease State Research in 2023 LAVAL, QC / ACCESSWIRE / December 1, 2022 / Salix Pharmaceuticals ("Salix"), the gastroenterology business of... Read More
November 29, 2022
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
LAVAL, QC / ACCESSWIRE / November 29, 2022 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB

  Research Tools
  News & Announcements
  Popular Topics
  Miscellaneous